Kasten, Benjamin B.
Houson, Hailey A.
Coleman, Jennifer M.
Leavenworth, Jianmei W.
Markert, James M.
Wu, Anna M.
Salazar, Felix
Tavaré, Richard
Massicano, Adriana V. F.
Gillespie, G. Yancey
Lapi, Suzanne E.
Warram, Jason M.
Sorace, Anna G.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (T32 NS048039)
U.S. Department of Defense (W81XWH-18-1-0315)
National Institutes of Health (R01AI148711)
American Cancer Society (RSG-18-006-01-CCE)
National Cancer Institute (R01CA24058)
Article History
Received: 26 April 2021
Accepted: 13 July 2021
First Online: 28 July 2021
Change Date: 8 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-021-00042-x
Competing interests
: AMW is a founder, board member, and consultant to ImaginAb, Inc., and a consultant to Avidity Biosciences. JMM and GYG have received funding from a structured buyout of Catherex, Inc., and each hold < 8% equity interest in Aettis, Inc, (Bala Cynwyd, PA) and < 25% interest in Treovir, LLC (Philadelphia, PA). GYG is Chief Scientific Officer of Treovir, LLC. Neither Aettis, Inc or Treovir, LLC own any interest in M002 or M032. All three companies had/have interests in oncolytic virotherapy. The other authors declare that they have no conflict of interest.